Breaking News


Results disclosed from PHOENIX 2 phase III study with ustekinumab in psoriasis


The PHOENIX 2 clinical trial evaluating Centocor's monoclonal antibody against interleukin 12/23p40, ustekinumab, was a randomized, double-blind, placebo-controlled study in 1230 patients with moderate to severe psoriasis. Patients were given either placebo or two ustekinumab doses of 45 or 90 mg s.c. 4 weeks apart followed by 45 or 90 mg every 12 weeks. Patients in the placebo group were crossed over to receive ustekinumab at weeks 12 and 16 and then every 12 weeks. By week 28, 70% and 79%, of patients on 45 and 90 mg, respectively, achieved Psoriasis Area and Severity Index (PASI) 75, 45% and 54%, respectively, achieved PASI90, and 19% and 30%, respectively, achieved PASI100. Furthermore, ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list